NAS10026,946−5.25%S&P7,428−3.39%GOLD$4,132+1.46%BTC$75,633−5.94%VIX23.84+43.53%latest tape · as of 18:03 UTC
The Screen · Healthcare · Drug Manufacturers - General
Johnson & Johnson
JNJ · a US exchange · USD · Market cap $662.5B · 138,200 employees
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Positioning political buying, disclosed 2026-09-25
Options put/call open interest 1.02, read 2026-11-05
Ethical passes the values gate
Price276.32 USD
Fair value268.05
Ethical score83.4/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-11-03Read Markup270.56+2.1% to today ✓Distribution gives way to Markup after a 7% rise in 2 weeks
2026-10-20Read Distribution253.28+9.1% to today Markdown gives way to Distribution after a 7% slide in 10 days
2026-10-10Read Markdown271.22+1.9% to today Accumulation gives way to Markdown with volume flow in agreement
2026-10-02Read Accumulation271.22+1.9% to today ✓Markup gives way to Accumulation after a 17% rise in 13 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Johnson & Johnson holds its Markup at $276.32. Consolidating, no directional conviction, held for 6 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 6 days
Price at the screen
$276.32
Valuation
41.76 trailing · 23.69 forward price to earnings
Values screen
PASS· score 83.4
Beta
0.21
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
24.06%
Below 33%
Interest-bearing debt is just 24.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.20%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
18.52%
Below 49%
Money owed to the company is 18.5% of assets, under the 49% limit.
Pass
Revenue purity
1.12%
Below 5%
Only 1.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Johnson & Johnson clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 24%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when JNJ's ethical verdict changes
Today JNJ passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic and this name passes it. Separately, community boycott lists cite this company: Cited by BDS movement for operating manufacturing and R&D facilities in Israel. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades above our $268.05 fair value estimate, strong competitive moat, 5.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 3.1% above the base estimate.
Where our models see it going: fair-value estimate $268.05, with a range of $191.69 to $319.49, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Healthcare Giant With a Heart
Imagine a company that's been around for over a century, providing healthcare solutions to the world. Johnson & Johnson fits that description, a household name in healthcare products, from pharmaceuticals to medical devices. With a strong moat and a consistent 7% revenue growth, it stands out as a reliable player in this critical field. Our fair value sits just above the current price, signaling a modest margin of safety.
The numbers back up Johnson & Johnson's standout status. A forward P/E of 21.7x, a profit margin of 21%, and an impressive ROE of 26% all underscore its financial strength. The consensus among 22 analysts is a buy, with a median target price above our fair value, suggesting a continued bullish outlook.
However, it's not all rosy. Johnson & Johnson is currently rated as overvalued by our metrics. While the ethical screen is a pass, the forward P/E and current price suggest caution. The risk here is that you're paying a premium for a company with a strong track record, but the current valuation may not leave much room for error. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
JNJ trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markup · changed$270.56+6.8%Entry 14
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253.
2026-10-27Distribution$253.28+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253.
2026-10-13Markdown$261.44+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-12Markdown$261.44-3.6%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-11Markdown$271.22+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-10Markdown · changed$271.22+0.0%Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253.
2026-09-03Markup$267.37+1.5%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253.
2026-08-03Markup$263.40+13.2%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
